



Q1FY26 Vinati Organics Ltd



Vinati Organics Ltd.

Miss on the top-line overshadowed margin outperformance, outlook supported by revenue growth

CMP*	Target	Potential Upside	Market Cap (INR Mn)	Recommendation	Sector
INR 1,675	INR 1,880	12.2%	INR 174,573	ACCUMULATE	Specialty Chemicals

Result Highlights

Financial Performance

Q1FY26 Revenue grew marginally by 3.3% YoY (-16.4% QoQ) to INR 5,420 Mn., stood below our estimates by 4.6%. Gross profit grew by healthy rate of 20.4% YoY (-7.7% QoQ) to INR 2837 Mn., resulting in improvement of gross margin by 744bps YoY (+496bps QoQ) to 52.3%.

EBITDA grew at a robust pace of 28.1% YoY (-11.5% QoQ) to INR 1,597 Mn., stood above our estimates by 6.7%, driven by significant improvement in gross margins. While management has guided EBITDA margins to remain in the range of 26.0 to 27.0%, margins for Q1FY26 came in significantly higher at 29.5% (+571bps YoY / +164bps QoQ). Net profit stood at INR 1,042 Mn, up 23.8% YoY (-15.3% QoQ), above our estimates by 4.8%, driven by improved operational performance.

Financial Guidance

Vinati Organics expects the revenue to grow at 20.0% CAGR over the FY24-FY27E, majorly led by strong contribution from ATBS segment, steady performance in butyl phenols, strong expansion in antioxidants. The Company expects the EBITDA margin to sustain in the range of 26.0%-27.0% over the medium to long term.

Vinati Organics plans to significantly scale its production capacity to maintain its leadership in the specialty chemical industry. It aims to expand its ATBS capacity by 50% from 40,000 MTPA to 60,000 MTPA over two phases with an outlay of INR 3,000 Mn., to capitalize on higher demand across Oil & gas and water treatment sectors. Phase I will witness capacity expansion by 25.0–30.0% (to be completed by June 2025), while the Phase II is expected to be operational by Q1FY26. Moreover, it plans to invest INR 5,000 Mn. for building capacities for adding high-margin niche products including MEHQ, Guaiacol, Iso Amylene and Anisole, which is expected to generate incremental revenue of INR 1bn by FY26E. The Company has earmarked CapEx of INR 3,600 Mn, for FY26 for improving capacity expansion, operational scalability and new product launches supported by ongoing R&D.

Valuation and Outlook:

We maintain a constructive stance on Vinati Organics' long-term outlook, supported by the expansion in ATBS capacities, improved utilization in Antioxidant segment and incremental contribution from the Veeral Organics facility, cementing its position in high-margin segments, leading to improved operating leverage and diversified revenue streams.

We have revised our FY26E/FY27E EPS estimates by -4.6%/-5.9%, respectively, as we factor in weaker revenue momentum, reflected in Q1FY26 performance, moderate improvement in EBITDA margins and lower other income. Margin resilience is expected to be driven by improvement in operating leverage led by significant capacity additions in ATBS segment, ramp-up of Antioxidants portfolio, new product launches and better product mix.

We have rolled forward our valuation basis to Jun'27 estimates. We value Vinati Organics at 34.0x Jun'27 EPS, implying a target price of INR 1,880.


We reiterate our "ACCUMULATE" rating on the stock.

KEY FINANCIALS

INR Millions	FY24	FY25	FY26E	FY27E	FY28E
Revenue	19,000	22,482	26,066	30,073	34,560
EBITDA	4,697	5,809	6,957	8,099	9,431
EBITDA Margin	24.7%	25.8%	26.7%	26.9%	27.3%
PAT	3,230	4,053	4,680	5,509	6,481
EPS	31.2	39.1	45.1	53.1	62.5

Source: Company, DevenChoksey Research

SHARE PRICE PERFORMANCE



MARKET DATA

Shares outs (Mn.)	103.7
Mkt Cap (INR Mn.)	174,573
52-Week H/L (INR)	2,135/1,412
3M Volume Avg (In '000)	73
Face Value (INR)	1.0
Bloomberg Code	VO IN

*Based on previous closing

Note: All the market data is as of previous closing

SHARE HOLDING PATTERN (%)

Particulars (%)	Jun-25	Mar-25	Dec-24
Promoters	74.3	74.3	74.3
FIIIs	3.9	3.8	5.3
DIIIs	9.2	9.2	7.6
Others	12.6	12.7	12.8
Total	100	100	100

15.7%





Revenue CAGR
between FY25-27E

16.6%

PAT CAGR
between FY25-27E

Vinati Organics Ltd.

Story in Charts



Source: Company, Deven Choksey Research


Vinati Organics Ltd.

Result Snapshot


Particulars (INR Mn)	Q1FY26	Q4FY25	Q1FY25	Q-o-Q	Y-o-Y
Revenue	5,420	6,485	5,247	(16.4%)	3.3%
Cost of Materials consumed	2,815	3,081	3,202	(8.6%)	(12.1%)
Purchase of Stock-in-trade	0	0	0	NA	NA
Changes in Inventories	-232	331	-311	(170.2%)	(25.3%)
Employee cost	424	375	336	12.9%	26.0%
Other Expenses	435	515	413	(15.6%)	5.4%
Power and fuel	382	378	360	0.8%	5.9%
EBITDA	1,597	1,804	1,247	(11.5%)	28.1%
EBITDA Margin (%)	29.5%	27.8%	23.8%	164bps	571bps
Depreciation & amortization	256	225	214	13.5%	19.6%
EBIT	1,341	1,579	1,033	(15.0%)	29.9%
Finance Cost	4	2	5	131.3%	(17.8%)
Other Income	74	62	93	20.0%	(20.2%)
PBT	1,412	1,639	1,121	(13.9%)	25.9%
Tax	370	409	280	(9.5%)	32.2%
PAT	1,042	1,230	841	(15.3%)	23.8%
Diluted EPS	10.1	11.9	8.1	(15.3%)	23.8%

Source: Company, Deven Choksey Research

Improvement in EBITDA margin was led by significant improvement in gross margins



Net margin witnessed significant expansion led by improved operational performance



Source: Company, Deven Choksey Research

Vinati Organics Ltd.

Change in Estimates:

Vinati Organics delivered a mixed Q1FY26 performance, with revenue at INR 5,420 Mn. (+3.3% YoY, -16.4% QoQ), stood below our estimates by 4.4%, while with EBITDA came in at INR 1,597 Mn., up 28.1% YoY, stood above our estimates by 6.7%. Stronger growth in EBITDA was driven by significant improvement in margins which came in at 29.5% compared to guidance range of 26.0–27.0%. Net profit grew at 23.8% YoY to INR 1,042 Mn., above our estimates. The Company expects revenue to grow at 20.0% CAGR and EBITDA margins to sustain in the range of 26.0–27.0% over the medium term, aided by large-scale capacity expansions, expected to drive improvement in operating leverage and support improved product mix.

We have revised our FY26E/FY27E EPS estimates by -4.6%/-5.9%, respectively, as we factor in weaker revenue momentum, reflected in Q1FY26 performance, moderate improvement in EBITDA margins and lower other income. Margin resilience is expected to be driven by improvement in operating leverage led by significant capacity additions in ATBS segment, ramp-up of Antioxidants portfolio, new product launches and better product mix.

	New Estimates			Old Estimates			Variation		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	26,066	30,073	34,560	26,978	31,834	NA	-3.4%	-5.5%	NM
EBITDA	6,957	8,099	9,431	7,122	8,404	NA	-2.3%	-3.6%	NM
EBITDA Margin (%)	26.7%	26.9%	27.3%	26.4%	26.4%	NA	29bps	53bps	NM
PAT	4,680	5,509	6,481	4,904	5,853	NA	-4.6%	-5.9%	NM
EPS	45.1	53.1	62.5	47.3	56.5	NA	-4.6%	-5.9%	NM

Source: Company, DevenChoksey Research

Valuation:

We have rolled forward our valuation basis to Jun'27 estimates. We value Vinati Organics at 34.0x Jun'27 EPS, implying a target price of INR 1,880.





We reiterate our “**ACCUMULATE**” rating on the stock.

Company	CMP	MCAP	Revenue CAGR	EBITDA CAGR	EBITDA Margin (%)	P/E		ROE (%)	
	INR	In Mn.	FY25-27E (%)	FY25-27E (%)	FY25	FY26E	FY27E	FY26E	FY27E
Vinati Organics	1,675	1,74,573	15.7%	18.1%	25.8%	34.7x	29.0x	15.5	15.9
Domestic Peers									
Clean Science & Technology	1,194	1,26,894	25.6%	23.1%	32.9%	39.1x	30.8x	20.7	22.0
Deepak Nitrite	1,820	2,48,235	10.4%	24.1%	10.0%	31.5x	25.7x	13.5	14.6
Mean			18.0%	23.6%	21.5%	35.3x	28.2x	17.1	18.3
Median			18.0%	23.6%	21.5%	35.3x	28.2x	17.1	18.3

Source: Company, DevenChoksey Research

Vinati Organics Ltd.

Valuation Charts



Source: Bloomberg Company, DevenChoksey Research

Vinati Organics Ltd.

KEY FINANCIALS

Exhibit 1: Profit & Loss Statement

INR Millions	FY25	FY26E	FY27E	FY28E
Revenue	22,482	26,066	30,073	34,560
COGS	11,960	13,658	15,843	18,119
Gross profit	10,522	12,409	14,230	16,441
Employee cost	1,396	1,727	1,990	2,298
Other expenses	1,804	2,054	2,255	2,592
EBITDA	5,809	6,957	8,099	9,431
EBITDA Margin	25.8%	26.7%	26.9%	27.3%
Depreciation	885	1,050	1,160	1,230
EBIT	4,924	5,908	6,939	8,201
Interest expense	5	19	19	19
Other income	443	374	425	460
PBT	5,362	6,263	7,345	8,642
Tax	1,309	1,582	1,836	2,160
Minority interest	0	0	0	0
PAT	4,053	4,680	5,509	6,481
Adj. EPS	39.1	45.1	53.1	62.5

Exhibit 3: Cash Flow Statement

INR Millions	FY25	FY26E	FY27E	FY28E
CFFO	4,582	3,808	3,311	5,058
Capex	(5,003)	(3,400)	(3,000)	(3,000)
Dividend Paid	(724)	(702)	(551)	(972)
Change in Capital	574	5	5	5
Closing Cash	5	75	242	1,769
FCF	(420)	408	311	2,058

Exhibit 4: Key Ratios

Key Ratios	FY25	FY26E	FY27E	FY28E
Gross Margin (%)	46.8%	47.6%	47.3%	47.6%
EBITDA Margin%	25.8%	26.7%	26.9%	27.3%
ROE%	14.5%	14.7%	14.9%	15.3%
ROCE%	18.1%	18.7%	19.1%	19.7%
P/E	40.4x	37.0x	31.5x	26.7x
EV/EBITDA	28.3	25.0	21.4	18.3

Source: Company, DevenChoksey Research

Exhibit 2: Balance Sheet

INR Millions	FY25	FY26E	FY27E	FY28E
Equity				
Equity Capital	104	104	104	104
Other Equity	27,829	31,807	36,765	42,275
Non controlling interest	0	0	0	0
Total Equity	27,933	31,911	36,869	42,379
Non-Current Liabilities				
Deferred tax liabilities (Net)	1,519	1,519	1,519	1,519
Other Liability	207	112	130	149
Total Non-Current Liabilities	1,725	1,631	1,648	1,668
Current Liabilities				
Borrowings	626	631	636	641
Trade Payables	1,485	1,695	2,170	2,482
Other financial liabilities	197	228	263	302
Other current liabilities	826	1,516	1,749	2,010
Total Current Liabilities	3,133	4,071	4,819	5,436
Total Liabilities	32,791	37,613	43,336	49,483
Non-Current Assets				
Property Plants and Equipments	17,237	19,587	21,427	23,197
CWIP	4,382	4,382	4,382	4,382
Investments	259	259	259	259
Other current assets	536	1,001	1,155	1,326
Total Non-Current Assets	22,413	25,229	27,222	29,164
Current Assets				
Inventories	2,212	2,565	3,296	3,787
Trade Receivables	5,923	6,927	9,063	10,415
Cash and Bank	5	75	242	1,769
Bank Balance	34	34	34	34
Other current assets	2,204	2,782	3,477	4,310
Total Current Assets	10,378	12,383	16,112	20,316
Total Assets	32,791	37,612	43,334	49,480

Vinati Organics Ltd.

Vinati Organics Ltd			
Date	CMP (INR)	TP (INR)	Recommendation
25-Aug-25	1,675	1,880	ACCUMULATE
20-May-25	1,830	2,033	ACCUMULATE
01-Feb-25	1,749	2,002	ACCUMULATE
14-Nov-24	1,835	2,002	ACCUMULATE
22-Aug-24	1,977	2,002	HOLD
28-May-24	1,766	1,795	HOLD
16-Feb-24	1,671	1,692	HOLD

Rating Legend (Expected over a 12-month period)	
Our Rating	Upside
Buy	More than 15%
Accumulate	5% – 15%
Hold	0 – 5%
Reduce	-5% – 0
Sell	Less than – 5%

ANALYST CERTIFICATION:

I, **Shank Gupta** (CA), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vide Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vide Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vide Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While we would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCFPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCFPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, **Shank Gupta** Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that **Shank Gupta**, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

The securities quoted are for illustration only and are not recommendatory.

DCFPL (Research Entity) and its research analysts uses Artificial Intelligence tools.

DCFPL and or its Research analysts shall be solely responsible for the security, confidentiality and integrity of the client data, use of any other information or data for research services, research services based on output of Artificial Intelligence tools and compliance with any law for the time being in force.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Investment in securities are subject to market risks, read all the documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Please send your feedback to research.retail@devenchoksey.com

DRChoksey FinServ Private Limited

CIN Number -U67100MH2020PTC352816

Registered Office and Corporate Office:

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058